Q-omics provides the consensus-scored PTCSC3 profile across patient tissues and cancer cell-line models. PTCSC3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PTCSC3 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, PTCSC3 RNA expression shows 15,370 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KIRC, and GBM as cancer lineages where PTCSC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTCSC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTCSC3 survival associations across molecular data types. PTCSC3 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTCSC3 RNA expression–survival associations across cancer types. High PTCSC3 expression shows unfavorable associations in BLCA, COAD and READ, but favorable associations in LUAD, KIRC and KIRP. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PTCSC3 RNA expression.
This table summarizes PTCSC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PTCSC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTCSC3 shows lower tumor expression in KIRC, KICH, THCA, KIRP and LUSC and higher tumor expression in HNSC. The KIRC box plot shows higher PTCSC3 RNA expression in normal versus tumor tissue (log2 FC = −2.862, t-test p < 0.001).
This table shows molecular features associated with PTCSC3 in patient tissues and cancer cell lines. In patient samples, PTCSC3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
